# Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Canonical URL: https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-reports-first-quarter-2026-financial-results-and-recent-portfolio-execution
Ticker: KNSA
Company: Kiniksa
Source: Kiniksa
Published: 2026-04-28 11:30 EST
Original Source URL: https://investors.kiniksa.com
## Summary

– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to

## Article Body
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to
## Recent Company News
- 2026-05-29 20:01 EST — [Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-upcoming-investor-conferences) — Source: Kiniksa
- 2026-04-28 11:30 EST — [Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution](https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-reports-first-quarter-2026-financial-results-and-recent-portfolio-execution) — Source: Kiniksa
- 2026-04-23 20:01 EST — [Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026](https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-april-28-2026) — Source: Kiniksa
- 2026-04-08 12:00 EST — [Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis](https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-launches-targeted-direct-to-consumer-tv-campaign-for-arcalystr-rilonacept-in-recurrent-pericarditis) — Source: Kiniksa
- 2026-02-25 21:01 EST — [Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference](https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-td-cowen-46th-annual-health-care-conference) — Source: Kiniksa
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)